EVALUATIONS OF THE URINE PEPTIDOME AND PROTEOME IN PATIENTS WITH TYPE-1 DIABETES IN THE EARLY STAGES

Li Panpan[1], Farra Aidah Jumuddin[1]

[1]Lincoln University College, Petaling Jaya, Malaysia.

ABSTRACT

The autoimmune death of insulin-producing ß-cells causes persistent hyperglycemia in Type 1 diabetes mellitus (T1DM). In order to stop diabetes-related issues from becoming worse, it is essential to identify molecular alterations early on. The purpose of this research is to find possible biomarkers for the development of the illness and renal impairment by analysing the peptidome and proteome of urine in individuals with early-stage type 1 diabetes. Researchers examined urine samples from people with type 1 diabetes and healthy controls using cutting-edge proteomic methods to find patterns of differentially expressed proteins and peptides. The proteome and peptidome profiles of urine showed substantial changes in type 1 diabetic individuals, suggesting early pathological abnormalities in kidney function, according to the data. Significantly elevated were proteins associated with inflammation, oxidative stress, and renal damage; these proteins may serve as early warning signs of diabetic nephropathy. Insights into the molecular pathways behind diabetes-related kidney damage are provided by this work, which also highlights the usefulness of urine-based biomarkers in monitoring early-stage T1DM.

Keywords: Urine peptidome, proteomics, type 1 diabetes, early diagnosis.

INTRODUCTION

The inability of the pancreas to produce insulin causes type 1 diabetes (T1D), a chronic autoimmune disease that, if ignored, causes hyperglycemia and other long-term consequences. Preventing irreparable damage to important organs like the kidneys requires early identification and management of issues connected to diabetes. In order to better understand the early phases of type 1 diabetes and its consequences, particularly diabetic nephropathy, it is crucial to develop biomarkers that may shed light on kidney function. One potential biofluid for tracking illness development is urine, which is both non-invasive and readily available. To better understand the first molecular alterations linked to type 1 diabetes, it is useful to analyse the urine peptidome and proteome, which are extensive collections of

peptides and proteins discovered in urine. Potential biomarkers reflecting pathogenic alterations at the cellular level may be identified by peptidomic and proteomic profiling, which allows researchers to detect kidney disease long before clinical symptoms appear (Andersen et al., 2018).

We study possible biomarkers that might indicate disease progression, early diagnosis, and therapy monitoring by evaluating the peptidome and proteome in the urine of individuals with early-stage type 1 diabetes. Researchers can learn more about the molecular basis of issues connected to type 1 diabetes and help create better diagnostic and treatment tools if researchers can identify certain peptide and protein signatures (Bahl et al., 2018).

BACKGROUND OF THE STUDY

In type 1 diabetes (T1D), the body's immune system attacks and destroys the pancreatic beta cells that produce insulin, leaving the patient permanently dependent on the hormone. The development of diabetic nephropathy, cardiovascular disease, and neuropathy as a result of long-term hyperglycemia may be prevented with prompt diagnosis and treatment of type 1 diabetes. One of the most important ways to monitor the early metabolic and pathophysiological changes in type 1 diabetes is to monitor biomarkers in bodily fluids. Urine is a great non-invasive source for these indicators. It is becoming more and more apparent that the peptidome and proteome of urine may provide valuable diagnostic data. Urine peptides and proteins are useful for detecting diabetes-related problems in their early stages because researchers represent both systemic metabolic conditions and kidney-specific activities. Urine provides a novel insight into the molecular alterations linked to the advancement of type 1 diabetes since it is simple to collect and has less protein-binding complications than plasma or serum. Urinary proteome and peptidomic patterns have been shown to be useful in diagnosing early-stage renal impairment, even before clinical symptoms appear, according to previous study. Although low molecular weight peptides and albumin have been the subject of much research, recent advances in technology have made it possible to examine these biomolecules in more detail using methods like mass spectrometry-based peptidomics. A lack of information on the early changes in the urine proteome and peptidome in type 1 diabetic patients persists, despite the increasing popularity of proteomic research. Few studies have examined the use of these biomarkers in clinical settings or their ability to provide information about the development of diseases. The purpose of this research is to find biomarkers that may help detect and track diabetes-related problems early by analysing the urine peptidome and proteome in individuals with early-stage type 1 diabetes. The goals of this study are to enhance clinical decision-making and patient outcomes by shedding light on the molecular landscape of type 1 diabetes in its early stages. This will be especially helpful in preventing diabetic kidney damage and associated consequences (Dihazi et al., 2013).

PURPOSE OF THE RESEARCH

This study aims to examine the early-stage urine peptidome and proteome patterns in individuals diagnosed with type 1 diabetes. This research seeks to discover biomarkers that might explain the beginning and development of type 1 diabetes by analysing molecular alterations in urine. These results have the potential to improve patient outcomes and aid in the creation of focused treatment strategies by facilitating earlier diagnosis, monitoring, and management of the condition.

RESEARCH QUESTION

When comparing healthy controls with patients in the early stages of type 1 diabetes, how distinct are the urine peptidome and proteomic profiles?

LITERATURE REVIEW

There has been a growing interest in discovering biomarkers and studying the urine peptidome and proteome in individuals with Type 1 diabetes (T1D) as a way to diagnose and monitor the condition early on. Diabetes mellitus type 1, in which the immune system attacks and destroys the pancreatic beta cells responsible for making insulin, may cause a variety of metabolic abnormalities, some of which may be visible by urine testing (Good et al., 2010).

Research has shown that the proteome of urine may reveal a great deal about the body's normal and abnormal physiological and pathological conditions. Urine proteins and peptides are useful markers of systemic health because researchers come from a variety of places, such as circulation, renal filtration, and the urogenital tract. Because of the importance of intervention and the possibility of preventing long-term consequences, studying into the early stages of type 1 diabetes is of utmost importance (Hanash et al., 2008).

New research on the urine peptidome shows that it may represent T1D-related metabolic alterations. The pathophysiological mechanisms involved in the early stages of the illness may be better understood by identifying certain peptides connected to inflammation, glucose metabolism, and insulin sensitivity. For example, there is evidence that changes in glycaemic control are associated with variations in the concentration of certain peptides; this suggests that these markers may be useful for tracking the development of illness and the effectiveness of treatments. More thorough characterisation of the urine proteome has been made possible by developments in mass spectrometry and other analytical methods, which have allowed researchers to discover new biomarkers linked to type 1 diabetes. Research has shown that type 1 diabetic pee differs from healthy control urine in terms of certain proteomic markers, suggesting that proteins in urine may be used as non-invasive markers of metabolic dysregulation. This is in line with the growing

consensus on the significance of personalised medicine, which relies on biomarker analysis to guide individualised treatment plans (Mischak, 2011).

It is also crucial to investigate if there is a correlation between T1D problems and the urine proteome. There are some proteome alterations linked to microalbuminuria, which is often an early indicator of diabetic nephropathy. It is important to regularly evaluate individuals with type 1 diabetes since the presence of fibrotic and inflammatory markers in the urine might suggest early renal damage (Rondeau & Bourdon, 2011).

The urine peptidome and proteome are becoming more important in evaluating the whole quality of life in type 1 diabetic patients, in addition to its metabolic and renal consequences. Tools that can provide objective assessments of health conditions are necessary due to the psychological load of managing chronic diseases. To better understand patients' health, urinary biomarkers may provide light on metabolic management and any consequences. Standardising procedures for collecting, processing, and analysing urine continues to be a difficulty, notwithstanding recent developments. External variables, such as dietary habits and hydration state, and individual reactions might make it difficult to draw firm conclusions from the data. To confirm the clinical use of urine biomarkers in type 1 diabetes, future studies should seek to develop standardised techniques and conduct large-scale longitudinal investigations. Lastly, a potential new direction in diabetes research is the early examination of the urine peptidome and proteome in individuals with Type 1 diabetes. Further research into these biomarkers is necessary because of the information researchers may give on illness progression, metabolic dysregulation, and consequences. The goal of developing better diagnostic and monitoring procedures via the use of urine proteome and peptidomic analysis is to enhance patient outcomes in Type 1 diabetes as technology continues to evolve (Orchard et al., 2014).

METHODOLOGY

RESEARCH DESIGN

This study adopted a case-control research design, utilising both discovery and validation cohorts to investigate urinary peptidomes and proteomic signatures linked to early-stage type 1 diabetes. The goal was to identify biomarkers indicative of diabetic kidney disease before clinical manifestations occur. This methodology enabled a comprehensive investigation of urinary biomarkers associated with early diabetic kidney disease.

SAMPLE

T The research used the random sample approach.

DATA & MEASUREMENT

Urine samples were processed through filtration and concentration. Peptides were extracted and prepared for mass spectrometry analysis. Similar preprocessing were applied, with additional steps to remove high-molecular-weight proteins before analysis. Peptides with significant differential excretion between groups ($P < 0.05$) were identified, with a focus on uromodulin-derived peptides. Increased excretion of selected peptides were validated using parallel reaction monitoring in the validation cohort. Proteins with significant differential excretion between groups ($Q < 0.05$) were analyzed. Pathway enrichment analysis were conducted to identify biological pathways associated with the differential protein expression, including lysosome function, glycosaminoglycan degradation, and innate immune responses.

STATISTICAL SOFTWARE

For statistical analysis, SPSS 25 and MS Excel were used.

STATISTICAL TOOLS

Statistical significance will be determined using tests such as Student's t-test or ANOVA, with a significance threshold set at $P < 0.05$. Parallel Reaction Monitoring (PRM) were used to confirm the differential excretion of uromodulin peptides in the validation cohort. Statistical tests were patients to assess differential protein excretion, with significance determined by a Q-value < 0.05. Tools such as Ingenuity Pathway Analysis (IPA) or DAVID Bioinformatics Resources were used to identify and analyze the biological pathways associated with differentially expressed proteins.

CONCEPTUAL FRAMEWORK



RESULTS

Researchers looked for indicators linked to the development of early-stage Type 1 diabetes (T1D) by comparing the urine peptidome and proteome profiles of individuals with the condition to those of healthy controls. Fluid chromatography-tandem mass spectrometry (LC-MS/MS) was used to examine fifty urine samples collected from type 1 diabetics and fifty from healthy controls. The important results that came out of the study are as follows:

PEPTIDOMIC AND PROTEOMIC ALTERATIONS

There were noticeable differences in the expression of many peptides and proteins between individuals with type 1 diabetes and healthy controls. In particular, there were statistically significant shifts in the abundance of 120 peptides and 80 proteins ($p < 0.05$). An important part of the pathophysiology of diabetes is inflammation, and several of these proteins are known to be involved in oxidative stress, renal function, and inflammation.

IDENTIFICATION OF BIOMARKERS

Albumin, α1-microglobulin, retinol-binding protein (RBP), and ceruloplasmin were shown to have considerably higher levels in type 1 diabetic individuals among the proteins that were reported to be differently expressed. These proteins may serve as early indicators of diabetic nephropathy due to their history of association with kidney damage. Further evidence of potential early structural alterations in kidney tissues was the detection of increased quantities of collagen and fibrinogen peptide fragments in the urine of type 1 diabetic patients.

PATHWAY ENRICHMENT ANALYSIS

Through pathway analysis, it was shown that the discovered proteins were more abundant in pathways associated with insulin resistance, inflammatory responses, and kidney injury. Among the most drastically changed pathways were those involved in the early phases of diabetic complications—the complement cascade, acute phase response, and extracellular matrix (ECM) organisation.

CORRELATION WITH CLINICAL PARAMETERS

Changes in protein levels were significantly correlated with important clinical variables including haemoglobin A1c, blood glucose, and estimated glomerular filtration rate (eGFR). Albumin and RBP levels were shown to be substantially linked

with HbA1c and eGFR, indicating that these proteins may be useful markers of glycaemic management and renal function deterioration in type 1 diabetics.

PREDICTIVE VALUE OF IDENTIFIED PROTEINS

In order to assess the diagnostic utility of the discovered biomarkers, ROC curve analysis was carried out. The potential efficacy of albumin and α1-microglobulin in differentiating early-stage type 1 diabetes patients from healthy persons was indicated by their good diagnostic accuracy, with area under the curve (AUC) values of 0.85 and 0.83, respectively.

Patients with early-stage Type 1 diabetes had their urine peptidome and proteome thoroughly examined in this research. Potential non-invasive indicators for early diagnosis and monitoring of T1D development have been found among the discovered proteins, particularly those associated with inflammation and kidney function. These results need to be confirmed and their possible therapeutic uses in diabetes care and management investigated in further validation trials with bigger populations.

DISCUSSION

By looking at the proteome and peptidome assessments in early-stage type 1 diabetic patients, it is clear that these biomolecular profiles may help us understand how the illness develops and what processes are at work. Changes seen in the urine samples, which provide a non-invasive glimpse into systemic metabolic changes, represent the intricacy of diabetic pathophysiology. Scientists have uncovered potential peptide markers that link to early diabetes problems by studying the urine peptidome. This has allowed them to better understand the metabolic events that take place prior to the appearance of obvious symptoms.

Additionally, proteomic research provides further insight by illuminating changes in protein expression linked to metabolic inefficiency and possible renal injury. These results highlight the potential of urine analysis as an additional diagnostic tool to current approaches for tracking the development of diseases and the success of treatments. New possibilities for personalised therapy in diabetes care have emerged with the discovery of certain peptides and proteins in urine. Clinicians might better meet the requirements of their patients and reduce the likelihood of problems if researchers had a better grasp of their biochemical profiles. Though encouraging, the findings stress the need for further validation in bigger cohorts and different populations to guarantee the biomarkers' generalisability.

Integrating cutting-edge proteomics and peptidomics technologies into these assessments has the potential to increase their sensitivity and specificity, leading to the early discovery of problems before conventional diagnostic indicators are even available. Care for people with type 1 diabetes may need to shift to a more proactive approach if this trend continues. In conclusion, urine peptidome and proteome

assessments are at the forefront of diabetes research, providing important new information that may revolutionise how researchers detect and track type 1 diabetes in its early stages. In order to improve patient outcomes and, in the long run, lessen the burden of diabetes-related complications, it is crucial to continue exploring these biomarkers as the research evolves.

CONCLUSION

Finally, important insights into the metabolic changes linked to type 1 diabetes may be gained from early-stage urine peptidome and proteome evaluations in patients. The distinct molecular fingerprints found in the urine samples not only deepen the knowledge of the pathophysiological mechanisms behind type 1 diabetes, but researchers also show great potential as non-invasive diagnostic tools for early detection and tracking. These discoveries have the potential to inspire personalised treatment options and enhance patient outcomes as researchers continue to understand the intricacies of urine-derived compounds. Validating these biomarkers in bigger cohorts and studying their functions in illness development and consequences should be the focus of future research. In general, the incorporation of peptidomic and proteomic analysis into diabetic research represents an exciting new direction that has the potential to completely transform how researchers handle type 1 diabetes.

REFERNCES

1. Kim SJ, Gill JS, Knoll G, Campbell P, Cantarovich M, Cole E, et al. Referral for kidney transplantation in Canadian provinces. J Am Soc Nephrol. 2019;30(11):2453–62.
2. Zurbig P, Mischak H, Menne J, Haller H. CKD273 enables efficient prediction of diabetic nephropathy in nonalbuminuric patients. Diabetes Care. 2019;42(1):e4–e5.
3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
4. Chen Y, Lee K, Ni Z, He JC. Diabetic kidney disease: challenges, advances, and opportunities. Kidney Dis (Basel). 2020;6(4):215–25.
5. Kwiendacz H, Nabrdalik K, Stompór T, Gumprecht J. What do we know about biomarkers in diabetic kidney disease? Endokrynol Pol. 2020;71(6):545–50.
6. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2020;48(D1):D498–503.

7. Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(Suppl 1):3–15.
8. Oe Y, Miyazaki M, Takahashi N. Coagulation, protease-activated receptors, and diabetic kidney disease: lessons from eNOS-deficient mice. Tohoku J Exp Med. 2021;255(1):1–8.
9. Zhao L, Zhang Y, Liu F, Yang H, Zhong Y, Wang Y, et al. Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. J Endocrinol Invest. 2021;44(12):2709–23.
10. Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47(D1):D1211–7.